Home Approach Product About News Contact News We're on a mission to improve patient outcomes. Our values guide us on our mission to accelerate the development of life-changing therapies.
No named decision-maker yet.
Careers mailbox is known
Sep 26
Posted 6 roles Paid Intern, Venture Intelligence Program, Contract Associate, Venture Intelligence
Sep 21
Raised a round Series A $25M · BetaKit
Sep 21
Raised a round Series A $25M · Associate, Network & Client Services crossed 90 days open
6 open
$224k stated pay, 6 roles
truth B 75 100% stale
Image without compromise: SpectraWAVE's flagship state-of-the-art intravascular imaging system is designed to help interventional cardiologists optimize PCI ...
Eman Namati · Executive Officer, Director · decision-maker
Martin Seifert · Executive Officer, Director · decision-maker
Brian Smith · Director
Bill Little · Director
Careers mailbox is known
Jun 5
Acquired Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI · spectrawave.com
2025
Team of 71 was 49 · US Form 5500 (plan participants)
Oct 9, 2025
New executive SpectraWAVE Appoints Dr. Jonathan Hill, MD as Chief Medical Officer · spectrawave.com
2017
Founded
Exact Imaging is the developer of ExactVu™, the world’s first micro ultrasound platform for targeted prostate biopsies in a single procedure.
Jerrold Wen · Executive Officer · decision-maker
Randy AuCoin · Executive Officer, Director · decision-maker
Rob Sandler · Executive Officer · decision-maker
Diane Lejeune · Director
Careers mailbox is known
Aug 16, 2019
Raised a round Venture round $244k · SEC Form D
Novel treatment solutions to address Type 2 Diabetes for patients, providers and healthcare systems around the world. In partnership with Mayo Clinic.
Robert Kukujlan · Executive Officer · decision-maker
Michael Brenzel · Executive Officer · decision-maker
Robert Kukuljan · Executive Officer · decision-maker
Paul Hindrichs · Executive Officer, Director · decision-maker
Careers mailbox is known
Jan 14, 2025
New executive Endogenex Appoints Krissy Wright as Chief Financial Officer · PRNewswire
Jun 13, 2024
Raised a round Venture round $69.6M · SEC Form D
2017
Founded
Damona Pharmaceuticals is developing precision neuromedicines to reverse cognitive deficits associated with brain disorders.associated with brain disorders.
No named decision-maker yet.
Careers mailbox is known
Cyrano Therapeutics is the leader in Smell Loss therapy and smell loss research. Recover your sense of smell today!
Richard Geoffrion · Executive Officer, Director · decision-maker
Robert Henkin · Director
Takahide Koda · Director
Gerry Brunk · Director
Careers mailbox is known
Jan 15, 2024
Raised a round Series B $9M
Now Enrolling: Clinical Trial for Type 1 Diabetes. See If You Qualify.
No named decision-maker yet.
Careers mailbox is known
Sep 27
Moved to Rippling
The Corvia® Atrial Shunt is designed to reduce symptoms associated with heart failure (HF), reduce HF hospitalizations, and improve quality of life.
Dan Curtis · Executive Officer · decision-maker
George Fazio · Executive Officer, Director · decision-maker
Irit Yaniv · Director
Gerald Brunk · Director
Careers mailbox is known
Jun 12, 2025
Raised a round Venture round $8.9M · SEC Form D
Dec 20, 2024
Certified Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards · corviamedical.com
2010
Founded
Degrading proteins.Saving lives.. Biotheryx is advancing a portfolio of first-in-class protein degraders, with an initial focus on validated targets in cancer and inflammatory disease.
Robert Williamson · Executive Officer, Director · decision-maker
Frank Mercurio · Executive Officer · decision-maker
David Stirling · Executive Officer, Director · decision-maker
Jaime Donadio · Executive Officer · decision-maker
Careers mailbox is known
May 7, 2024
Certified Biotheryx Announces U.S. FDA Clearance of Investigational New Drug Application for BTX-9341, a First-In-Class, Dual Bifunctional Degrader of CDK4/6 · biotheryx.com
Feb 23, 2022
Board appointment BioTheryX Appoints Nancy Miller-Rich as Chair of Its Board of Directors · PRNewswire
May 19, 2021
Raised a round Venture round $92.1M · SEC Form D
Discover proactive heart failure management with the FDA-approved Cordella platform that guides care and improves outcomes based on pulmonary artery (PA) pressure and vital sign data.
John Flavin · Executive Officer · decision-maker
Kent Elmer · Executive Officer · decision-maker
Anthony Nunez · Executive Officer · decision-maker
Harry Rowland · Executive Officer, Director · decision-maker
Careers mailbox is known
Sep 14, 2018
Raised a round Series D $45M
Mark McPartland · Executive Officer · decision-maker
Mary Brisson · Executive Officer · decision-maker
Peter Weiler · Executive Officer · decision-maker
Stephen Lemieux · Executive Officer · decision-maker
No careers mailbox known
Jun 16
Raised a round Venture round $3.5M · SEC Form D
Redefining heart failure by enabling early & safe treatment - Puzzle Medical Devices® Inc. is a Canadian company specializing in the development of a minimally invasive long-term hemodynamic transcatheter pump.
No named decision-maker yet.
Careers mailbox is known
Gene therapy for advanced coronary artery disease. XyloCor Therapeutics is focused on improving the lives of patients through our commitment to advancing novel therapies for coronary artery disease.
No named decision-maker yet.
Careers mailbox is known
Mar 5
New executive XyloCor Appoints John Tucker as President and Chief Executive Officer · YahooFinance
G1 Therapeutics, Inc. is a commercial stage oncology company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer.
Mark Velleca · Executive Officer, Director · decision-maker
Gregory Mossinghoff · Executive Officer · decision-maker
Frederic Eshelman · Director
Seth Rudnick · Director
Careers mailbox is known
Apr 27, 2016
Raised a round Venture round $50M · SEC Form D
Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.) is a privately owned company based in Montreal, Quebec, Canada.
No named decision-maker yet.
Careers mailbox is known
Aug 15, 2023
Certified Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Present… · krqe.com
Nov 29, 2022
Board appointment Thryv Therapeutics Inc. announces the appointment of Pharmaceutical Commercialization Expert Melissa Koomey, M.B.A., to its Board of Directors · Nasdaq
AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.
No named decision-maker yet.
No careers mailbox known
KisoJi Biotechnology. Breakthrough antibody discovery forbreakthrough therapeutics.
No named decision-maker yet.
No careers mailbox known
Oct 24, 2024
Partnership Cancer Research UK and KisoJi Biotechnology Collaborate to Advance the First Naked Antibody Against TROP2 Into the Clinic · PRNewswire
Biotechnology company pioneering reversible male contraception. Our products, NES/T and ADAM, are daily and long-lasting options in clinical testing today.
Kevin Eisenfrats · Executive Officer, Director · decision-maker
Iris Van Alderwerelt van Rosenburgh · Director
Michael King · Director
Tom Thorpe · Director
Careers mailbox is known
Jun 3
Raised a round Series B $92.5M · led by BVF Partners L.P · Pulse 2.0
Mar 30, 2022
New executive Contraline Appoints Medical Device Industry Leader Dr. Yelena Tropsha as Chief Technology Officer · businesswire
2017
Founded
We are a drug discovery company that is uniquely harnessing the power of protein dynamics, biophysics, machine learning and computational chemistry.
No named decision-maker yet.
No careers mailbox known
HistoSonics® is developing a non-invasive, robotically assisted platform capable of destroying tissue at a sub-cellular level.
Richard Bosler · Executive Officer · decision-maker
Mike Daniel · Executive Officer · decision-maker
Dan Bulver · Executive Officer · decision-maker
Josh King · Executive Officer · decision-maker
No careers mailbox known
Jul 13
Certified HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization · businesswire.com
2025
Team of 267 was 198 · US Form 5500 (plan participants)
Jul 31, 2024
Raised a round Series D $102M · SEC Form D
2019
Founded
